BREAST Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent breast cancer surgery between 2015 and 2025.

LUNG Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent lung cancer surgery between 2015 and 2025.

COLON Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent colon cancer surgery between 2015 and 2025.

BLADDER Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent bladder cancer surgery between 2015 and 2025.

PANCREAS Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent pancreas cancer surgery between 2015 and 2025.

PROSTATE Cancers Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent prostate cancer between 2015 and 2025.

MYELOMA Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent myeloma between 2015 and 2025.

INFLAMMATORY BOWEL DISEASE (IBD) Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent IBD between 2015 and 2025.

SKIN INFLAMMATORY DISEASE Project:
Objective: Development and validation of new biomarkers, as well as diagnostic and therapeutic management support algorithms.
Patients involved: Patients who underwent skin diseases between 2015 and 2025.